Brainstorm Cell Therapeutics Inc. (BCLI): Business Model Canvas [Jan-2025 Updated]

Brainstorm Cell Therapeutics Inc. (BCLI) stands at the cutting edge of regenerative medicine, pioneering revolutionary cell therapies that offer hope to patients battling devastating neurological disorders. By leveraging their groundbreaking NurOwn mesenchymal stem cell technology, the company is transforming the landscape of treatment for conditions like ALS and Parkinson's, where traditional medical approaches have fallen short. Their innovative business model represents a bold fusion of scientific innovation, strategic partnerships, and a profound commitment to addressing unmet medical needs, positioning BCLI as a potential game-changer in the complex world of cellular therapeutics.

Brainstorm Cell Therapeutics Inc. (BCLI) - Business Model: Key Partnerships

Collaboration with Academic Research Institutions

Brainstorm Cell Therapeutics has established research partnerships with the following academic institutions:

Institution	Collaboration Focus	Year Established
Massachusetts General Hospital	Neurological disease research	2017
Harvard Medical School	Stem cell therapeutic development	2019

Strategic Partnerships with Neurological Disease Treatment Centers

The company has developed strategic partnerships with specialized treatment centers:

• NYU Langone Health Neurology Department
• Cleveland Clinic Neurological Institute
• Johns Hopkins Hospital Neurology Center

Funding and Research Support from Government Grants

Brainstorm Cell Therapeutics has secured government research funding:

Funding Agency	Grant Amount	Research Purpose
National Institutes of Health (NIH)	$2.3 million	ALS stem cell therapy research
Department of Defense	$1.7 million	Neurological disease treatment development

Potential Pharmaceutical Development Alliances

Current potential pharmaceutical development partnerships include:

• Novartis AG - Preliminary discussions for neurological therapeutic collaboration
• Biogen Inc. - Exploratory partnership for stem cell technology integration
• AbbVie Inc. - Potential research alliance for neurodegenerative disease treatments

Brainstorm Cell Therapeutics Inc. (BCLI) - Business Model: Key Activities

Developing Regenerative Cell Therapies for Neurological Disorders

Brainstorm Cell Therapeutics focuses on developing NurOwn® technology, a proprietary autologous cell therapy platform. The company has invested approximately $120 million in research and development as of 2023.

Research Area	Investment	Current Stage
NurOwn® Technology	$120 million	Advanced Clinical Trials
ALS Treatment	$45 million	Phase 3 Clinical Trials
Parkinson's Research	$35 million	Preclinical Development

Conducting Clinical Trials for NurOwn Technology

The company has completed multiple clinical trials across different neurological conditions.

• Completed 3 Phase 3 clinical trials for ALS
• Conducted 2 Phase 2 trials for Parkinson's disease
• Ongoing clinical trials in multiple neurological disorders

Researching Stem Cell Treatment for Neurological Conditions

Condition	Research Focus	Current Progress
ALS	Mesenchymal Stem Cell Therapy	Advanced Clinical Stage
Parkinson's Disease	Neuronal Regeneration	Preclinical Research
Multiple Sclerosis	Immunomodulation	Early Stage Investigation

Pursuing Regulatory Approvals for Innovative Cell Therapies

Brainstorm has engaged with FDA and EMA for potential therapy approvals.

• Submitted Biologics License Application (BLA) for NurOwn® in ALS
• Ongoing regulatory interactions for Parkinson's disease treatment
• Accumulated over 250 patient data points in clinical trials

Brainstorm Cell Therapeutics Inc. (BCLI) - Business Model: Key Resources

Proprietary NurOwn Mesenchymal Stem Cell Technology

NurOwn technology platform involves autologous mesenchymal stromal cells (MSCs) that are designed to secrete neurotrophic factors.

Technology Characteristic	Specific Details
Patent Status	Multiple issued patents in United States and international jurisdictions
Development Stage	Advanced clinical development for neurodegenerative diseases
Unique Mechanism	Targeted cellular therapy approach

Specialized Research and Development Team

Brainstorm's R&D team comprises specialized scientific professionals focused on neurological disease treatments.

• Total R&D Personnel: Approximately 25-30 researchers
• PhD Level Researchers: Approximately 15
• Cumulative Research Experience: Over 150 years combined

Intellectual Property Portfolio

IP Category	Number of Assets
Issued Patents	12
Patent Applications	8
Geographical Coverage	United States, Europe, Israel

Advanced Laboratory and Research Facilities

Brainstorm maintains specialized cellular manufacturing and research infrastructure.

• Primary Research Location: Hackensack, New Jersey
• Cell Manufacturing Facility: cGMP compliant
• Research Equipment Investment: Approximately $3.2 million

Clinical Trial Data and Scientific Expertise

Clinical Trial Metric	Quantitative Data
Completed Clinical Trials	5
Ongoing Clinical Trials	3
Total Patient Enrollment	Approximately 250 patients

Brainstorm Cell Therapeutics Inc. (BCLI) - Business Model: Value Propositions

Innovative Regenerative Cell Therapy Solutions

Brainstorm Cell Therapeutics focuses on developing NurOwn® technology, a proprietary cell therapy platform targeting neurological disorders.

Technology Platform	Key Characteristics
NurOwn® Technology	Personalized mesenchymal stem cell treatment
Cell Modification Process	Induces cells to secrete neurotrophic factors

Potential Breakthrough Treatments for Neurological Disorders

Primary therapeutic focus areas include:

• Amyotrophic Lateral Sclerosis (ALS)
• Parkinson's Disease
• Multiple Sclerosis

Personalized Stem Cell Therapeutic Approaches

Treatment Characteristic	Specific Details
Patient-Specific Cells	Derived from patient's own bone marrow
Customization Level	Highly personalized cellular therapy

Hope for Patients with Limited Treatment Options

Clinical trial data demonstrates potential therapeutic benefits for patients with limited alternative treatments.

Advanced Cellular Technology Targeting Unmet Medical Needs

Technology Aspect	Unmet Medical Need
Neurotrophic Factor Secretion	Neurological disease progression mitigation
Regenerative Potential	Neuronal protection and potential repair

Brainstorm Cell Therapeutics Inc. (BCLI) - Business Model: Customer Relationships

Direct Engagement with Patient Communities

Brainstorm Cell Therapeutics maintains direct patient engagement strategies for neurological disease research, specifically focusing on ALS (Amyotrophic Lateral Sclerosis) patient populations.

Patient Community Engagement Metrics	2024 Data
Total Patient Support Network	475 registered patients
Annual Patient Information Sessions	12 virtual and in-person events
Patient Feedback Channels	3 dedicated communication platforms

Transparent Communication about Clinical Trial Progress

The company maintains rigorous communication protocols for clinical trial transparency.

• NurOwn® clinical trial update frequency: Quarterly reports
• Published clinical trial results: 2 comprehensive publications in 2023
• Patient communication channels: Website, email newsletters, medical conference presentations

Medical Professional Outreach and Education

Brainstorm Cell Therapeutics implements targeted medical professional engagement strategies.

Professional Outreach Metrics	2024 Data
Neurologist Network Engagement	287 active neurological specialists
Annual Medical Conference Presentations	5 international conferences
Continuing Medical Education (CME) Programs	3 specialized workshops

Patient Support and Information Programs

Comprehensive patient support infrastructure designed to provide comprehensive information and resources.

• Dedicated patient support helpline: Available 5 days/week
• Online resource portal: Multilingual information access
• Patient assistance program enrollment: 215 active participants

Collaborative Research Approach with Medical Institutions

Strategic collaborations with leading medical research institutions enhance customer relationship management.

Research Collaboration Details	2024 Data
Active Research Partnerships	7 international medical institutions
Joint Research Funding	$3.2 million allocated
Collaborative Publication Outputs	4 peer-reviewed research papers

Brainstorm Cell Therapeutics Inc. (BCLI) - Business Model: Channels

Direct Medical Conferences and Presentations

Brainstorm Cell Therapeutics utilizes scientific conferences for channel communication. In 2023, the company participated in:

Conference	Date	Location
American Academy of Neurology Annual Meeting	April 2023	Boston, MA
International Stem Cell Conference	September 2023	San Francisco, CA

Scientific Publications and Research Journals

Publication channels include:

• Annals of Neurology
• Stem Cell Reports
• Journal of Neurological Sciences

Investor Relations Communications

Investor communication channels:

Channel	Frequency
Quarterly Earnings Calls	4 times per year
Annual Shareholder Meeting	1 time per year
Investor Presentations	6-8 times per year

Clinical Trial Recruitment Platforms

Recruitment channels include:

• ClinicalTrials.gov
• NIH Clinical Research Trials
• Neurology Patient Registries

Partnerships with Neurology Treatment Centers

Partner Institution	Collaboration Focus
Massachusetts General Hospital	ALS Research
Stanford Neuroscience Institute	Stem Cell Therapy Development
NYU Langone Health	Clinical Trial Coordination

Brainstorm Cell Therapeutics Inc. (BCLI) - Business Model: Customer Segments

Patients with ALS and other Neurological Disorders

Brainstorm Cell Therapeutics targets approximately 16,000 ALS patients in the United States. Global ALS patient population estimated at 450,000 individuals worldwide.

Patient Segment	Population Size	Annual Incidence
ALS Patients (US)	16,000	5,000 new cases/year
Global ALS Patients	450,000	140,000 new cases/year

Neurologists and Medical Specialists

Target market includes approximately 6,500 neurologists in the United States specializing in neurodegenerative disorders.

• Neurologists treating ALS: Estimated 1,200 specialists
• Academic medical centers focused on neurodegenerative research: 120 institutions

Research Institutions

Brainstorm Cell Therapeutics collaborates with multiple research centers focusing on neurological disorders.

Research Institution Type	Number of Potential Collaborators
Academic Research Centers	85
Neuroscience Research Institutes	42

Healthcare Providers

Target healthcare providers include specialized neurology clinics and ALS treatment centers.

• Specialized ALS treatment centers in US: 48
• Neurology clinics capable of advanced cell therapy: 320

Patient Advocacy Groups

Collaboration with national and international ALS advocacy organizations.

Advocacy Group Type	Number of Organizations
National ALS Organizations	12
International ALS Advocacy Groups	25

Brainstorm Cell Therapeutics Inc. (BCLI) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, Brainstorm Cell Therapeutics reported R&D expenses totaling $16.4 million.

Expense Category	Amount ($)
NurOwn® Technology Development	8,200,000
Preclinical Research	3,600,000
Clinical Trial Preparation	4,600,000

Clinical Trial Management Costs

Clinical trial expenses for 2023 were approximately $12.7 million, focused on neurological disease indications.

• ALS Clinical Trials: $6,500,000
• Multiple Sclerosis Trials: $4,200,000
• Supportive Study Costs: $2,000,000

Intellectual Property Protection

Annual intellectual property protection expenditures were $1.2 million in 2023.

IP Protection Type	Cost ($)
Patent Filing	650,000
Legal Consultation	350,000
Maintenance Fees	200,000

Regulatory Compliance Investments

Regulatory compliance costs for 2023 totaled $2.5 million.

• FDA Submission Preparation: $1,200,000
• Regulatory Consulting: $800,000
• Compliance Documentation: $500,000

Personnel and Specialized Scientific Talent

Personnel expenses for specialized scientific talent were $9.3 million in 2023.

Personnel Category	Annual Cost ($)
Research Scientists	4,500,000
Clinical Researchers	2,800,000
Administrative Support	2,000,000

Brainstorm Cell Therapeutics Inc. (BCLI) - Business Model: Revenue Streams

Potential Future Therapeutic Product Sales

As of 2024, Brainstorm Cell Therapeutics focuses on potential revenue from NurOwn® technology for neurological disorders, specifically targeting ALS and other neurodegenerative conditions.

Product	Potential Market	Estimated Revenue Potential
NurOwn® for ALS	Neurological Disorder Treatment	$12-15 million projected annual potential

Research Grants and Government Funding

Brainstorm Cell Therapeutics secures funding through various research grants and government support mechanisms.

Funding Source	Amount (2023-2024)	Purpose
National Institutes of Health (NIH)	$2.3 million	Neurological Research Support

Potential Licensing of Proprietary Technologies

The company's intellectual property represents a significant potential revenue stream.

• NurOwn® cellular technology licensing potential
• Neurological disorder treatment patent portfolio
• Estimated licensing revenue range: $5-8 million annually

Strategic Partnership Agreements

Collaborative agreements provide additional revenue opportunities.

Partner	Agreement Type	Potential Financial Impact
Tier-1 Pharmaceutical Company	Research Collaboration	$3.5 million milestone payments

Investor Funding and Capital Raises

Capital raising activities contribute to the company's financial resources.

Funding Round	Amount Raised	Date
Private Placement	$6.2 million	Q4 2023

Total Potential Revenue Streams: Approximately $20-25 million annually